Nasdaq

TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
Seeking Alpha

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ® ...
Morningstar

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...
Hosted on MSN

J&J posts long-term trial data for injectable Tremfya in ulcerative colitis

J&J (NYSE: JNJ) previously posted 12-week SC induction data from ASTRO, noting that Tremfya, approved in the U.S. as SC and IV induction options for ulcerative colitis as well as Crohn's disease, ...
Morningstar

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...
Healio

Tremfya outperforms IL-17 inhibitors in treatment persistence for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tremfya showed greater persistence in bio-naïve and ...